AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Ads

You May Also Like

Immunicum AB (publ) Delårsrapport Q2 2018

Pressmeddelande 17 augusti 2018 Immunicum AB (publ) Delårsrapport Q2 2018 April - juni i ...

UPDATE – Amydis Awarded Prion Disease Grant from NIH

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company ...